Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ558MR)

This product GTTS-WQ558MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ558MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11452MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ12741MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ13149MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ8807MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ3884MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ4764MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ11278MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ9136MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW